Furthermore, we evaluated for the first time whether the immunization protocols, including the Cp 090104 strain and the CP-derived BLPs, together with the pneumococcal vaccines can enhance the resistance to secondary pneumococcal pneumonia induced after inflammatory lung damage mediated by the activation of the viral pattern recognition receptor TLR3. The gene discussed is CP; the disease is pneumococcal pneumonia.